

Novel Combretastatin A-4 Analogues with Potent Cytotoxicity and Anti-Tubulin Polymerization Activities

Background

The microtubule system of eukaryotic cells is widely regarded as a potent target for the development of anti-cancer agents. The α - and β -tubulin heterodimer is the building block of microtubules and, as such, is the biochemical target for several clinically used chemotherapeutics. Colchicine, paclitaxel and other clinically used anti-tubulin drugs often face limitations such as neural and systemic toxicity, poor water solubility and bioavailability, and complex synthetic pathways and isolation procedures. The present invention describes five novel small-molecule compounds that exhibit anti-tubulin polymerization and anti-cancer activity.

Description of the Technology

The present invention describes the rational design, synthesis and biological evaluation of a series of novel small-molecule compounds that exhibit strong *in vitro* anti-tubulin polymerization activity as well as cytotoxicity in the low nM range against four cancer cell lines isolated from cervical, breast and colon tumors. Moreover, these compounds show significant cytotoxicity in human cervix epithelial adenocarcinoma and colon carcinoma cells which overexpress multiple drug resistance. Furthermore, these novel inhibitors are water soluble and predicted to exhibit good bioavailability. These compounds and their analogues are also attractive from the standpoint of medicinal chemistry and large-scale chemical synthesis, by virtue of the absence of chiral (stereochemical) centers and the efficient 5-step reaction scheme which renders the desired product in high yield employing inexpensive starting materials.

Advantages

- . •Compounds are water soluble
- . •Good bioavailability
- . •Ease of manufacturing
- . •Water Soluble

Applications

- Compounds of this invention can be used as anti-cancer agents

Patent Status

Provisional patent application filed.

Licensing Opportunity

This technology is available for exclusive license.

Contact

Peter Golikov, MS, MBA
Director, Ventures and Licensing
University of Medicine and Dentistry of New Jersey
335 George Street
New Brunswick, NJ 08901
Direct Phone: (732)-235-9355
Main Office Phone: (732)-235-9350
Facsimile: (732)-235-9358
golikope@umdnj.edu

File RWJ 04-29/Welsh